- Home
- Oncology latest news
Oncology latest news
Below you’ll find the most recent oncology news across Johnson & Johnson.
Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
Updated results for talquetamab monotherapy and in combination with daratumumab highlighted in oral presentations at the 2022 EHA Annual Congress
Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations
Data from RAGNAR, the largest tumor-agnostic study reported for a targeted therapy and the first to evaluate FGFR-driven malignancies, featured in oral presentation at the 2022 ASCO Annual Meeting
Updated Data for Janssen’s Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study evaluating the BCMAxCD3 bispecific antibody, including progression-free survival and subgroup analyses Data from MajesTEC-1 study published in The New England Journal of Medicine
Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
At nearly 28 months of median follow-up, median progression-free survival and overall survival were not yet reached Data presented at the 2022 ASCO Annual Meeting and published in the Journal of Clinical Oncology
Phase 3 SHINE Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma
Primary results from the first frontline Phase 3 study of a Bruton’s tyrosine kinase inhibitor in MCL to be presented as late-breaking data at the 2022 ASCO Annual Meeting and also published in The New England Journal of Medicine
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
Studies spanning industry-leading hematologic malignancies portfolio and pipeline with new research in solid tumor therapies to highlight precision medicine and targeted therapy strategies
European Commission Grants Conditional Approval of CARVYKTI® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
In the pivotal clinical study CARTITUDE-1, 98 percent of patients with relapsed or refractory multiple myeloma responded to a one-time treatment with ciltacabtagene autoleucel and 80 percent of patients who responded experienced a stringent complete response [1]
MPAACT Consortium Unites Industry and Academia to Establish Measurable Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Drug Development
Validated Measurable Residual Disease Assays are Critical for the Rapid Development of Future Novel Therapeutics for Patients with Acute Myeloid Leukemia
Janssen Seeks Approval of a New Indication for IMBRUVICA® (ibrutinib) for Use in Patients with Untreated Mantle Cell Lymphoma
Application based on Phase 3 SHINE study results, which investigated the safety and efficacy of all-oral ibrutinib in combination with bendamustine and rituximab in adult patients with previously untreated mantle cell lymphoma[1]
Janssen Presents New Data Demonstrating the Combination of Niraparib and Abiraterone Acetate Plus Prednisone Significantly Improved Radiographic Progression-Free Survival as a First-Line Therapy in Patients with HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
Initial results from Phase 3 MAGNITUDE study, to be featured in a late-breaking oral presentation at ASCO GU, highlight subset of patients with mCRPC most likely to benefit from treatment
New ERLEADA® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Real-world evidence study demonstrates majority of patients with mCSPC achieved over 90 percent decline in PSA by six months after initiation of ERLEADA® Rapid and deep PSA decline is associated with improved health-related quality of life in advanced prostate cancer as shown by separate post-hoc analysis of patient-reported outcomes from Phase 3 SPARTAN and TITAN studies
News Archive
Looking for more news? Visit the archive to see a full list of oncology updates from the past several years.
More from Johnson & Johnson
From Aha! moment to FDA approval: The fascinating story behind a new treatment for bladder cancer
For National Cancer Prevention Month, we retrace the 22-year journey it took to bring a potentially life-changing treatment for an aggressive form of bladder cancer to patients who may benefit most.
He beat childhood cancer. Now he’s trying to save lives as a cancer researcher
Brad Heidrich’s diagnosis with a deadly cancer at age 13 changed the course of his life—and inspired the person he would become: a Janssen scientist dedicated to working on therapies for blood cancer. For National Cancer Survivor Month, we share his incredible story.
Lung cancer: What you need to know about your risk factor—even if you’ve never smoked
Some 20% of people diagnosed with the disease haven’t touched a cigarette. For Healthy Lung Month, scientists who’ve dedicated their research to defeating lung cancer discuss why early detection is so key—and what you can do to protect yourself.